Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986148 |
| Synonyms | |
| Therapy Description |
BMS-986148 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against mesothelin (MSLN) linked to the anti-microtubule agent tubulysin, which may result in cytotoxic effects in mesothelin-expressing tumor cells (PMID: 34615718). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986148 | BMS986148|BMS 986148 | MSLN Antibody 13 | BMS-986148 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against mesothelin (MSLN) linked to the anti-microtubule agent tubulysin, which may result in cytotoxic effects in mesothelin-expressing tumor cells (PMID: 34615718). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02341625 | Phase Ib/II | BMS-986148 BMS-986148 + Nivolumab | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | Terminated | USA | NLD | ITA | GBR | CAN | BEL | AUS | 0 |